✨ Free AI Report
Allogene Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Allogene Therapeutics, Inc.
Company Research

Allogene Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Allogene Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing allogeneic CAR T (chimeric antigen receptor T cell) therapies for cancer treatment. Founded in 2018 and...

Analyst-debate audio for Allogene Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Allogene Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Company OverviewProduct PortfolioLeadership and Management TeamFinancial OverviewMarketing StrategiesMarket Overview and Competitors
Get Interactive Report Freeor start reading below
Live on AskCyborg
6/10Solid
Allogene Therapeutics, Inc.

De-risked biotech with critical 2026 inflection points in oncology (ALPHA3) and autoimmune (ALLO-329) programs that could reshape CAR T therapeutics if successful.

▶︎ Listen to the 90-second analyst debate
Competitors covered:Novartis AG
6/ 10Solid

Cyborg Score thesis

De-risked biotech with critical 2026 inflection points in oncology (ALPHA3) and autoimmune (ALLO-329) programs that could reshape...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Cell Therapy (Allogeneic CAR-T)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest Allogene Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Allogene Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing allogeneic CAR T (chimeric antigen receptor T cell) therapies for cancer treatment. Founded in 2018 and headquartered in South San Francisco, California, Allogene Therapeutics is at the forefront of innovation in cancer immunotherapy, aiming to deliver off-the-shelf CAR T therapies that are more accessible and affordable than traditional autologous approaches.

Company Overview

Pro stress-test →

Allogene Therapeutics, Inc. focuses on creating allogeneic CAR T therapies designed to treat various types of cancer. The company’s mission is to accelerate the development of CAR T therapies by overcoming the limitations associated with autologous treatments, such as high costs, lengthy manufacturing times, and limited patient accessibility.

Product Portfolio

Pro stress-test →

Allogene’s product portfolio includes multiple allogeneic CAR T therapies in different stages of development. Their lead product candidates, ALLO-501 and ALLO-501A, target CD19-positive hematologic malignancies such as non-Hodgkin lymphoma. Additionally, they are developing ALLO-715 for relapsed/refractory multiple myeloma and ALLO-605, an enhanced CAR T therapy for multiple myeloma.

Leadership and Management Team

Pro stress-test →

The leadership team at Allogene Therapeutics comprises industry veterans with extensive experience in biotechnology and oncology. Key members include:

  • David Chang, M.D., Ph.D. – President, CEO, and Co-Founder
  • Arie Belldegrun, M.D. – Executive Chairman and Co-Founder
  • Rafael Amado, M.D. – Executive Vice President of Research and Development and Chief Medical Officer
  • Alison Moore, Ph.D. – Chief Technical Officer

Financial Overview

As a publicly traded company (Nasdaq: ALLO), Allogene Therapeutics, Inc. has secured significant funding through multiple rounds of financing. The company utilizes these resources to advance its robust pipeline of product candidates. Key financial metrics such as revenue, R&D expenditure, and cash runway indicate a strong financial position to support ongoing research and development activities.

Marketing Strategies

Allogene Therapeutics employs a strategic marketing approach focused on building awareness and support within the medical and patient communities. Leveraging scientific publications, conference presentations, and collaborations with academic institutions, the company positions itself as a leader in allogeneic CAR T therapy research and development.

Market Overview and Competitors

The market for CAR T therapies is highly competitive, with several key players, including Kite Pharma, Novartis, and Juno Therapeutics. Allogene Therapeutics differentiates itself by focusing exclusively on allogeneic CAR T therapies, which offer distinct advantages such as scalability and reduced manufacturing times. The global CAR T therapy market is expected to grow significantly, driven by increasing cancer prevalence and advancements in immunotherapy.

Sales Strategies

Allogene Therapeutics plans to leverage partnerships with pharmaceutical companies, healthcare providers, and key opinion leaders to drive the adoption of its therapies. The company aims to establish a robust distribution network to ensure broad access to its innovative treatments once they receive regulatory approval.

Technologies Utilized

Allogene Therapeutics utilizes cutting-edge technologies, including TALEN gene-editing technology, to develop its allogeneic CAR T therapies. These technologies enable precise modifications to T cells, enhancing their safety and efficacy in targeting cancer cells while minimizing the risk of graft-versus-host disease.

HR Practices

Allogene Therapeutics is committed to fostering a collaborative and inclusive work environment. The company prioritizes employee development through continuous learning opportunities, competitive compensation packages, and comprehensive benefits. Allogene also emphasizes diversity and inclusion in its hiring practices.

Corporate Responsibility

Allogene Therapeutics is dedicated to corporate social responsibility, actively engaging in initiatives that support patients, communities, and the environment. The company participates in various cancer awareness and support programs, as well as sustainability efforts to minimize its environmental footprint.

Future Plans

Looking ahead, Allogene Therapeutics aims to advance its pipeline of product candidates through clinical trials and regulatory approvals. The company is also exploring new indications and potential combinations with other therapies to enhance the efficacy of its treatments. Continued investment in research and development, strategic partnerships, and market expansion are key components of Allogene’s growth strategy.

Our detailed report on Allogene Therapeutics, Inc. delves deeper into each of these aspects, providing comprehensive insights and analyses. Subscribers to AskCyborg.com gain exclusive access to in-depth company profiles, financial data, market trends, and expert commentary to make informed decisions.


Get your detailed report on Allogene Therapeutics, Inc. by subscribing

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Allogene Therapeutics, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Allogene Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare Allogene Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Allogene Therapeutics, Inc. operates in Biopharmaceutical / Cell Therapy (Allogeneic CAR-T). See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Cell Therapy (Allogeneic CAR-T) research →
NEW · MCP server

Ask your AI assistant about Allogene Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Allogene Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Allogene Therapeutics, Inc. do this quarter?”
“Is Allogene Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Allogene Therapeutics, Inc. do?+
Allogene Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing allogeneic CAR T (chimeric antigen receptor T cell) therapies for cancer treatment. Founded in 2018 and...
What is Allogene Therapeutics, Inc.'s Cyborg Score?+
Allogene Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Allogene Therapeutics, Inc.'s main competitors?+
Named competitors include Yescarta, Kymriah, Tecartus. The full competitive landscape is in the AskCyborg report.
How can I get the full Allogene Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Allogene Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Allogene Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Company Research

Gambling and Lotteries Industry BriefingStationery and Office Products Industry BriefingDefense Tech Industry BriefingAi Infrastructure Systems Industry BriefingPet Insurance Industry BriefingSelf-Storage Industry BriefingMetal Additive Manufacturing Industry BriefingAi Accelerator Hardware Systems Industry BriefingLuxury Wines & Spirits Industry BriefingEnzymatic Plastic Recycling Industry BriefingInfrastructure as a Service (IaaS) Industry Briefingluxury fashion apparel Industry Briefing

Explore Industry Research

Travel Insurance Industry Company Research ReportSecurity Services Industry Company Research ReportLandscaping and Grounds Maintenance Industry Company Research ReportJanitorial and Cleaning Services Industry Company Research ReportSustainability Consulting Industry Company Research ReportReal Estate Investment Trusts (REITs) Industry Company Research Report
Browse All Company ResearchBrowse All Industry ResearchRSS Feed